ASCO GI 2021 | RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab in MSI/dMMR mCRC

Romain Cohen, MD, PhD, Saint-Antoine Hospital, AP-HP, Paris, France, discusses the results of the GERCOR NIPICOL Phase II study (NCT03350126) evaluating the RECIST and iRECIST criteria for the management of microsatellite instability or mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC) patients treated with nivolumab and ipilimumab. The results of the study suggest pseudoprogression is rare in these patients, and that the combined immune checkpoint blockade therapy results in impressive disease control rates and survival outcomes. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).